Camilla Huse Bondesson, MBA

Chair of Board

Camilla has over 35 years of experience in commercial roles within the Life Science industry. Camilla has extensive experience gained in commercial, marketing, and executive roles, as well as a broad understanding of the business dynamics within labtech, medtech, diagnostics, and pharma service companies in an international context. Since 2004, Camilla is working as a board professional, business consultant, coach and mentor. This covers listed companies as well as start-up businesses. She currently holds three board positions, two of which are Chair.

Marianne Hansson, Ph.D.

Board Member

Marianne Hansson has more than 20 years of experience in executive positions in life science companies. For 12 years, she was CEO of Atlas Antibodies AB and, during the pandemic, CEO of A05 Diagnostics AB. She currently serves as part-time CEO of ProteomEdge AB, Amylonix AB, and Zytox Therapeutics AB. She holds a Ph.D. in Biochemistry from the Royal Institute of Technology in Stockholm

Philippe Stas, MBA

Board Member

Philippe has over 20 years' experience in the CRO space holding several executive positions. Prior to co-founding ImmunXperts, an Immunnogenicity CRO in 2014 (now IQVIA) and leading Trinean, a life science tools company till 2017 (now Unchained Labs), he initiated the bio-informatics service provider and CRO Algonomics  (now Lonza) in the late 90s. Philippe is currently supporting White Fund, a MedTech investment fund, and helping entrepreneurs build companies as an independent board member. Philippe is an INSEAD-certified director (IDP-C) and holds an M.Sc.Eng. in Biotechnology (V.U.Brussels), a M.Sc. in IT (UHasselt) and holds an MBA (Liverpool U.).

Fredrik Frejd, Ph.D.

Board Member

Fredrik Frejd has over 25 years of experience in life science research and 20+ years of industrial biopharmaceuticals experience, with particular expertise in biologics drug development. Dr. Frejd is the Chief Scientific Officer of Affibody AB and has led several projects from discovery through preclinical development, including immunotoxicological assessments, into phase 1, 2, and 3 clinical trials. Dr Frejd is also an adjunct professor in cancer precision medicine with a strong translational focus at Uppsala University. In 2021, Dr. Frejd co-founded the radiotherapeutics company Akiram AB, where he is currently a board member. Dr. Frejd holds a Master in Molecular Biology (Stockholm University, Sweden) and received his Ph.D. from the Swiss Federal Institute of Technology, ETH, in Zurich in 2001. Dr. Frejd is a scientific advisory board member at the Center for Molecular Bioengineering (B CUBE) at Dresden University of Technology, Germany.